The new contract is expected to increase both production and reduce production costs targeting increased sales volume and market share.
Imatinib’s market in Russia for 2012 amounted to slightly less than $200m, according to JSC F-Synthesis.
The tyrosine-kinase inhibitor drug is used in the treatment of multiple cancers, especially Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
The targeted therapy works by preventing the growth of cancer cells and eliminating them by apoptosis.